{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:04:04Z","timestamp":1780549444031,"version":"3.54.1"},"reference-count":152,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Background: Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis characterized by chronic inflammation, endothelial dysfunction, and high residual risk of major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs). This review aimed to summarize the prognostic role of inflammatory biomarkers in PAD and to discuss their therapeutic implications. Methods: A comprehensive narrative review was performed using PubMed\/MEDLINE, Scopus, Web of Science, and Cochrane Library, focusing mainly on English-language studies published in recent years. Randomized trials, observational studies, systematic reviews, and meta-analyses evaluating inflammatory biomarkers and anti-inflammatory or vasculoprotective therapies in PAD were included. Results: Both classical and emerging inflammatory biomarkers were associated with PAD severity and adverse outcomes. C-reactive protein, fibrinogen, interleukins, tumor necrosis factor-\u03b1, myeloperoxidase, galectin-3, and growth differentiation factor-15 showed prognostic value for MACEs, MALEs, restenosis, amputation, and mortality. Among newer indices, the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, C-reactive protein-to-albumin ratio, and HALP (Hemoglobin, Albumin, Lymphocyte, and Platelet) score appear especially promising for risk stratification. Anti-inflammatory and pleiotropic therapies, including canakinumab, colchicine, statins, and PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors, may help reduce residual inflammatory risk. Conclusions: Inflammatory biomarkers may improve prognostic stratification and support more personalized management in PAD. Their integration into clinical practice could enhance limb preservation and long-term cardiovascular outcomes.<\/jats:p>","DOI":"10.3390\/biom16060789","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:36:56Z","timestamp":1779892616000},"page":"789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Inflammatory Biomarkers in Peripheral Arterial Disease: A Comprehensive Review of Prognostic and Therapeutic Implications"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6775-0287","authenticated-orcid":false,"given":"Andreea","family":"Tudurachi","sequence":"first","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-8624","authenticated-orcid":false,"given":"Bogdan-Sorin","family":"Tudurachi","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7925-3806","authenticated-orcid":false,"given":"Larisa","family":"Anghel","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu Andy","family":"Sasc\u0103u","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea Ovanez","family":"Balasanian","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Prisacariu","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Bazyani","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-4561","authenticated-orcid":false,"given":"Cristian","family":"St\u0103tescu","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700503 Ia\u0219i, Romania"},{"name":"Cardiology Department, Cardiovascular Diseases Institute \u201cProf. Dr. George I. M. Georgescu\u201d, 700503 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Reitz, K.M., Althouse, A.D., Forman, D.E., Zuckerbraun, B.S., Vodovotz, Y., Zamora, R., Raffai, R.L., Hall, D.E., and Tzeng, E. (2023). MetfOrmin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC): Randomized clinical trial protocol. BMC Cardiovasc. Disord., 23.","DOI":"10.1186\/s12872-023-03047-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/1358863X241281699","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with peripheral artery disease: A systematic review and meta-analysis","volume":"29","author":"Kurniawan","year":"2024","journal-title":"Vasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1540-8183.2010.00548.x","article-title":"Predictors of poor outcome in female patients undergoing endovascular intervention","volume":"23","author":"Abbas","year":"2010","journal-title":"J. Interv. Cardiol."},{"key":"ref_4","first-page":"553","article-title":"Peripheral Artery Disease: A High-Risk Yet Understudied, Underdiagnosed, and Undertreated Condition-A Call to Action","volume":"38","author":"Mastracci","year":"2022","journal-title":"Can. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC Guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yu, Z., Lu, B., Han, R., and Tu, C. (2025). Exploring the hemoglobin-to-red blood cell distribution width ratio (HRR) to peripheral arterial disease nexus: A comprehensive analysis of NHANES data from 1999 to 2004. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1529155"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1038\/s41598-023-35073-z","article-title":"NT-proBNP as a surrogate for unknown heart failure and its predictive power for peripheral artery disease outcome and phenotype","volume":"13","author":"Zierfuss","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Achim, A., Peter, O.A., Cocoi, M., Serban, A., Mot, S., Dadarlat-Pop, A., Nemes, A., and Ruzsa, Z. (2023). Correlation between Coronary Artery Disease with Other Arterial Systems: Similar, Albeit Separate, Underlying Pathophysiologic Mechanisms. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10050210"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/ATVBAHA.124.319396","article-title":"Differences in Stable and Unstable Atherosclerotic Plaque","volume":"44","author":"Kawai","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/ATVBAHA.119.312864","article-title":"Pathologic Disparities Between Peripheral Artery Disease and Coronary Artery Disease","volume":"40","author":"Narula","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"117616","DOI":"10.1016\/j.atherosclerosis.2024.117616","article-title":"Sex-related differences in coronary and carotid vessel geometry, plaque composition and shear stress obtained from imaging","volume":"395","author":"Wentzel","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Russo, M., Gurgoglione, F.L., Russo, A., Rinaldi, R., Torlai Triglia, L., Foschi, M., Vigna, C., Vergallo, R., Montone, R.A., and Benedetto, U. (2025). Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features. Life, 15.","DOI":"10.3390\/life15081226"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-physiol-030212-183802","article-title":"The adventitia: Essential regulator of vascular wall structure and function","volume":"75","author":"Stenmark","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/STROKEAHA.110.597328","article-title":"Discriminating carotid atherosclerotic lesion severity by luminal stenosis and plaque burden: A comparison utilizing high-resolution magnetic resonance imaging at 3.0 Tesla","volume":"42","author":"Zhao","year":"2011","journal-title":"Stroke"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70146","DOI":"10.1111\/apha.70146","article-title":"DDR1 Regulates Femoral Arterial Calcification in Lower-Extremity Artery Disease Through NF-Kappa B Activation","volume":"242","author":"Thakur","year":"2026","journal-title":"Acta Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000096744","article-title":"Calcifications, arterial stiffness and atherosclerosis","volume":"44","author":"Mackey","year":"2007","journal-title":"Adv. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17539447221096940","DOI":"10.1177\/17539447221096940","article-title":"MicroRNAs in peripheral artery disease: Potential biomarkers and pathophysiological mechanisms","volume":"16","author":"Ring","year":"2022","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70144","DOI":"10.1111\/eci.70144","article-title":"Implications of inflammation and sex in lower extremity arterial disease","volume":"56","author":"Schnidrig","year":"2026","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3892\/etm.2022.11639","article-title":"Neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratios are associated with amputation rates in patients with peripheral arterial disease and diabetes mellitus who underwent revascularization: A Romanian regional center study","volume":"24","author":"Cosarca","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary Medical Management of Peripheral Artery Disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1479164120914845","DOI":"10.1177\/1479164120914845","article-title":"Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control","volume":"17","author":"Hobaus","year":"2020","journal-title":"Diab Vasc. Dis. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jvs.2021.02.026","article-title":"A systematic review and meta-analysis on the association between C-reactive protein levels and adverse limb events after revascularization in patients with peripheral arterial disease","volume":"74","author":"Di","year":"2021","journal-title":"J. Vasc. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.avsg.2021.09.030","article-title":"C-reactive Protein, Free Fatty Acid, and Uric Acid as Predictors of Adverse Events after Endovascular Revascularization of Arterial Femoropopliteal Occlusion Lesions","volume":"81","author":"Di","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12933-023-01872-x","article-title":"Development of a biomarker panel for assessing cardiovascular risk in diabetic patients with chronic limb-threatening ischemia (CLTI): A prospective study","volume":"22","author":"Nardella","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Popescu, A.I., Rata, A.L., Barac, S., Popescu, R., Onofrei, R.R., Vlad, C., and Vlad, D. (2024). Narrative Review of Biological Markers in Chronic Limb-Threatening Ischemia. Biomedicines, 12.","DOI":"10.3390\/biomedicines12040798"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/10408363.2025.2512472","article-title":"Association of inflammatory biomarkers with morbidity and mortality risk in patients with peripheral artery disease: A systematic review and -meta-analysis","volume":"62","author":"Ozben","year":"2025","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1161\/ATVBAHA.120.314774","article-title":"Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis","volume":"40","author":"Kremers","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Song, P., Xiong, H., Quan, X., Chen, Q., Wang, D., Liu, X., and Shi, M. (2025). Predictive factors and models for major adverse cardiovascular and limb events in patients with peripheral arterial disease. Vasa.","DOI":"10.1024\/0301-1526\/a001228"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s00380-021-01863-6","article-title":"Long-term impact of high-sensitivity C-reactive protein in patients with intermittent claudication due to peripheral artery disease following endovascular treatment","volume":"36","author":"Fukase","year":"2021","journal-title":"Heart Vessel."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Saenz-Pipaon, G., Martinez-Aguilar, E., Orbe, J., Gonzalez Miqueo, A., Fernandez-Alonso, L., Paramo, J.A., and Roncal, C. (2021). The Role of Circulating Biomarkers in Peripheral Arterial Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073601"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.avsg.2022.07.009","article-title":"Inflammation and Loss of Skeletal Muscle Mass in Chronic Limb Threatening Ischemia","volume":"88","author":"Ferreira","year":"2023","journal-title":"Ann. Vasc. Surg."},{"key":"ref_32","first-page":"135","article-title":"Novel biomarkers for cardiovascular risk prediction","volume":"14","author":"Wang","year":"2017","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e031922","DOI":"10.1161\/JAHA.123.031922","article-title":"Reversion of the Inflammatory Markers in Patients With Chronic Limb-Threatening Ischemia","volume":"13","author":"Ferreira","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vieceli Dalla Sega, F., Cimaglia, P., Manfrini, M., Fortini, F., Marracino, L., Bernucci, D., Pompei, G., Scala, A., Trichilo, M., and De Carolis, B. (2022). Circulating Biomarkers of Endothelial Dysfunction and Inflammation in Predicting Clinical Outcomes in Diabetic Patients with Critical Limb Ischemia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810641"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kokalj, N., and Jug, B. (2025). Prognostic Impact of Interleukin-27 in Peripheral Artery Disease. Life, 15.","DOI":"10.3390\/life15111768"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2337\/dc19-0408","article-title":"Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes","volume":"42","author":"Biscetti","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Caicedo, D., Alvarez, C.V., Perez-Romero, S., and Devesa, J. (2022). The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-alpha Hypothesis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020489"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Buso, G., Faggin, E., Bressan, A., Galliazzo, S., Cinetto, F., Felice, C., Fusaro, M., Erdmann, A., Pauletto, P., and Rattazzi, M. (2023). Biomarkers of Neutrophil Activation in Patients with Symptomatic Chronic Peripheral Artery Disease Predict Worse Cardiovascular Outcome. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030866"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41598-023-50751-8","article-title":"Association of immunologic findings of atheromatous plaques with subsequent cardiovascular events in patients with peripheral artery disease","volume":"14","author":"Kim","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.31083\/j.rcm2504124","article-title":"High Serum Galectin-3 Level as a Potential Biomarker of Peripheral Artery Disease in Patients Undergoing Hemodialysis","volume":"25","author":"Chiu","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2021.11.016","article-title":"Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality","volume":"341","author":"Ursli","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Li, B., Shaikh, F., Younes, H., Abuhalimeh, B., Zamzam, A., Abdin, R., and Qadura, M. (2025). Investigation of Growth Differentiation Factor 15 as a Prognostic Biomarker for Major Adverse Limb Events in Peripheral Artery Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155239"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"964","DOI":"10.5551\/jat.64515","article-title":"Growth Differentiation Factor-15 and Clinical Outcomes in Lower Extremity Artery Disease","volume":"31","author":"Shikama","year":"2024","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jvs.2023.05.001","article-title":"Fatty acid binding protein 4 has prognostic value in peripheral artery disease","volume":"78","author":"Li","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12933-022-01650-1","article-title":"Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: A prospective study of a diabetic population","volume":"21","author":"Rando","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12933-022-01605-6","article-title":"Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease","volume":"21","author":"Kadoglou","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Poredos, P., Sabovic, M., Bozic Mijovski, M., Nikolajevic, J., Antignani, P.L., Paraskevas, K.I., Mikhailidis, D.P., and Blinc, A. (2022). Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231912054"},{"key":"ref_48","first-page":"138","article-title":"Inflammatory-Related Biomarkers in Patients Undergoing Percutaneous Transluminal Angioplasty for Femoropopliteal Artery Lesions","volume":"41","author":"Baytugan","year":"2025","journal-title":"Acta Cardiol. Sin."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Onofrei, V., Crisan, A., Adam, C.A., Marcu, D.T.M., Haba, M.S.C., Tribus, L.C., Ceasovschih, A., Esanu, I.M., Petroaie, A.D., and Crisan-Dabija, R. (2023). The Role Played by Novel Inflammatory Markers in Assessment of Peripheral Artery Disease. Medicina, 59.","DOI":"10.3390\/medicina59091557"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.avsg.2022.06.005","article-title":"Neutrophil-To-Lymphocyte Ratio as a Predictive Tool for Post-Operative Outcomes in Patients Undergoing Open Lower Extremity Revascularization Procedures","volume":"87","author":"Adler","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Russu, E., Muresan, A.V., Arbanasi, E.M., Kaller, R., Hosu, I., Voidazan, S., Arbanasi, E.M., and Cosarca, C.M. (2022). The Predictive Role of NLR and PLR in Outcome and Patency of Lower Limb Revascularization in Patients with Femoropopliteal Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092620"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Yamamoto, Y., Kazama, A., Kikuchi, T., and Kudo, T. (2025). Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictor of Clinical Outcomes in Patients Undergoing Femoral Endarterectomy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14010211"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Huang, Z., Ni, X., and Dai, Q. (2025). Predictive Value of Lymphocyte-Based Inflammation Index for Clinical Outcome in Patients With Lower Extremity Arteriosclerosis Obliterans: A Systematic Review and Meta-Analysis. Angiology, 33197251399864.","DOI":"10.1177\/00033197251399864"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/00033197221102222","article-title":"Relationship Between Neutrophil-Lymphocyte Ratio and Drug-Coated Balloon Restenosis in Patients With Femoropopliteal Arterial Disease","volume":"74","author":"Pan","year":"2023","journal-title":"Angiology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/15385744251387577","article-title":"The Relationship Between Neutrophil-to-Lymphocyte Ratio and Restenosis in Patients With Femoropopliteal Chronic Total Occlusion Treated With Drug-Coated Balloon Alone Versus Combined Atherectomy and Drug-Coated Balloon","volume":"60","author":"Toz","year":"2026","journal-title":"Vasc. Endovasc. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, Z., Sheng, L., Gu, H., Yang, F., Xie, H., and Li, M. (2022). Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.868656"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/1708538120986294","article-title":"Critical limb ischemia patients clinically improving with medical treatment have lower neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios","volume":"29","author":"Erdogan","year":"2021","journal-title":"Vascular"},{"key":"ref_58","first-page":"504","article-title":"Impact of nutritional and inflammatory status in patients with critical limb-threatening ischemia","volume":"40","year":"2021","journal-title":"Int. Angiol."},{"key":"ref_59","first-page":"112","article-title":"Neutrophil-lymphocyte ratio as a link between complex pedal ulcers and poor clinical results after infrainguinal surgical revascularization","volume":"40","author":"Varela","year":"2021","journal-title":"Int. Angiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"442","DOI":"10.23736\/S0392-9590.21.04699-X","article-title":"Elevated neutrophil to lymphocyte ratio is associated with decreased amputation-free survival after femoropopliteal percutaneous revascularization","volume":"40","author":"King","year":"2021","journal-title":"Int. Angiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Su, M.I., and Liu, C.W. (2021). Neutrophil-to-lymphocyte ratio associated with an increased risk of mortality in patients with critical limb ischemia. PLoS ONE, 16.","DOI":"10.21203\/rs.3.rs-243462\/v1"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Arbanasi, E.M., Muresan, A.V., Cosarca, C.M., Kaller, R., Bud, T.I., Hosu, I., Voidazan, S.T., Arbanasi, E.M., and Russu, E. (2022). Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Impact on Predicting Outcomes in Patients with Acute Limb Ischemia. Life, 12.","DOI":"10.3390\/life12060822"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejvs.2021.03.011","article-title":"Pre-operative Neutrophil to Lymphocyte Ratio is Associated With 30 Day Death or Amputation After Revascularisation for Acute Limb Ischaemia","volume":"62","author":"Coelho","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.avsg.2025.10.026","article-title":"Inflammatory Biomarkers and Outcomes in Acute Lower Limb Ischemia: A Systematic Review and Meta-Analysis","volume":"123","year":"2026","journal-title":"Ann. Vasc. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Babes, E.E., Radu, A.F., Cretu, N.A., Bungau, G., Diaconu, C.C., Tit, D.M., and Babes, V.V. (2025). Risk Stratification in Acute Coronary Syndromes: The Systemic Immune-Inflammation Index as Prognostic Marker. Med. Sci., 13.","DOI":"10.3390\/medsci13030116"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1532\/hsf.5303","article-title":"Systemic Immune-Inflammation Index Predicts Restenosis after Interventions for Lower Extremity Arteriosclerosis Obliterans","volume":"26","author":"Tian","year":"2023","journal-title":"Heart Surg. Forum"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Murat, B., Aydin, F., Sener, E., Ozden, B., Kaya, I.C., Heval, A., and Murat, S. (2025). Impact of the Pre-Procedural Pan-Immune Inflammation Value on Long-Term Mortality in Patients With Peripheral Artery Disease Following Endovascular Treatment: A Comparative Study. Angiology, 33197251383344.","DOI":"10.1177\/00033197251383344"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Dragan, A., Dragan, A.S., and Stiru, O. (2024). The Predictive Value of Perioperative Inflammatory Indexes in Major Arterial Surgical Revascularization from Leriche Syndrome. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216338"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1358863X251320867","article-title":"Predictive value of the inflammatory indices on wound healing in patients with chronic limb-threatening ischemia revascularized via percutaneous intervention","volume":"30","author":"Guler","year":"2025","journal-title":"Vasc. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.avsg.2025.06.027","article-title":"The Aggregate Index of Systemic Inflammation: A Novel Inflammatory Marker for Predicting Restenosis Risk in Superficial Femoral Artery Lesions after Endovascular Treatment","volume":"120","author":"Erdogan","year":"2025","journal-title":"Ann. Vasc. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.avsg.2021.11.008","article-title":"Association Between CRP\/Albumin Ratio and Long-Term Mortality in Patients With cHronIc Limb-Threatening Ischemia Undergoing EndovaScular Therapy Below The Knee: The ACHILES-BTK Registry","volume":"82","author":"Panc","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"20251280","DOI":"10.1515\/med-2025-1280","article-title":"C-reactive protein-to-albumin ratio in peripheral artery disease","volume":"20","author":"Saputra","year":"2025","journal-title":"Open Med."},{"key":"ref_73","first-page":"1058","article-title":"Correlation between C-reactive protein to albumin ratio and restenosis after femoral popliteal stenting in patients with lower extremity arteriosclerotic obliterans","volume":"61","author":"Wang","year":"2023","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/00033197221075853","article-title":"Elevated C-Reactive Protein\/Albumin Ratio Is Associated With Lesion Complexity, Multilevel Involvement, and Adverse Outcomes in Patients With Peripheral Artery Disease","volume":"73","author":"Kim","year":"2022","journal-title":"Angiology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/17085381251327000","article-title":"Assessing the prognostic value of HALP score in peripheral artery disease: Correlation with lesion severity and long-term mortality","volume":"34","author":"Evsen","year":"2025","journal-title":"Vascular"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/17085381251330370","article-title":"The role of the HALP score in determining the severity of lower extremity peripheral arterial disease","volume":"34","author":"Tunca","year":"2025","journal-title":"Vascular"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1358863X19859072","article-title":"A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease","volume":"24","author":"Russell","year":"2019","journal-title":"Vasc. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1097\/MS9.0000000000004053","article-title":"Inflammation-modulating agents in chronic limb-threatening ischemia: A narrative review of therapeutic potential and future directions","volume":"88","author":"Gaur","year":"2026","journal-title":"Ann. Med. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Grajek, S., Michalak, M., Urbanowicz, T., and Olasinska-Wisniewska, A. (2021). A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.740896"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.mayocp.2024.05.004","article-title":"Effects of Colchicine on Major Adverse Limb and Cardiovascular Events in Patients With Peripheral Artery Disease","volume":"99","author":"Lin","year":"2024","journal-title":"Mayo Clin. Proc."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"oeae062","DOI":"10.1093\/ehjopen\/oeae062","article-title":"Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: Emulation of target trials","volume":"4","author":"Heindel","year":"2024","journal-title":"Eur. Heart J. Open"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: A meta-analysis of trials","volume":"46","author":"Poorthuis","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejvs.2025.05.004","article-title":"Low Dose Colchicine in Patients with Peripheral Artery Disease to Address Residual Vascular Risk (LEADER-PAD) Trial: Relevance and Importance of a Global Initiative","volume":"70","author":"Jansen","year":"2025","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"118563","DOI":"10.1016\/j.atherosclerosis.2024.118563","article-title":"Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study","volume":"398","author":"Tramujas","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","article-title":"Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention","volume":"7","author":"Kong","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_91","first-page":"100481","article-title":"Baseline inflammatory status affects the prognostic impact of statins in patients with peripheral arterial disease","volume":"47","author":"Jujo","year":"2024","journal-title":"Am. Heart J. Plus"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjcard.2022.09.018","article-title":"Prognostic Impact of Statins on Patients With Peripheral Artery Disease With Elevated C-Reactive Protein Levels","volume":"186","author":"Shibahashi","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Cecchini, A.L., Biscetti, F., Manzato, M., Lo Sasso, L., Rando, M.M., Nicolazzi, M.A., Rossini, E., Eraso, L.H., Dimuzio, P.J., and Massetti, M. (2023). Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216099"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.carrev.2024.10.006","article-title":"Effect of evolocumab in patients with chronic limb threatening ischemia (Evol-CLI study)","volume":"76","author":"Dhillon","year":"2025","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1522\u20131529, 1529e1521-1526","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: Results from TRA2degreesP-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: Results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Shah, A.J., Pavlatos, N., and Kalra, D.K. (2023). Preventive Therapies in Peripheral Arterial Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123157"},{"key":"ref_99","first-page":"200590","article-title":"Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis","volume":"29","author":"Hamzah","year":"2026","journal-title":"Int. J. Cardiol. Cardiovasc. Risk Prev."},{"key":"ref_100","first-page":"1","article-title":"The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)","volume":"55","author":"Clavijo","year":"2023","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"754","DOI":"10.5551\/jat.57653","article-title":"Effects of PCSK9 Inhibitor on Favorable Limb Outcomes in Patients with Chronic Limb-Threatening Ischemia","volume":"28","author":"Sato","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Angoulvant, D., Peyronnet, E., Cariou, B., Amarenco, P., Boccara, F., Boissel, J.P., Bastien, A., Courcelles, E., Diatchenko, A., and Filipovics, A. (2025). Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: The SIRIUS In-Silico modelling of cardiovascular outcomes. Eur. J. Prev. Cardiol.","DOI":"10.1093\/eurjpc\/zwaf783"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Belur, A.D., Shah, A.J., Virani, S.S., Vorla, M., and Kalra, D.K. (2022). Role of Lipid-Lowering Therapy in Peripheral Artery Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164872"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_107","first-page":"747","article-title":"Efficacy and safety of bempedoic acid in the prevention of cardiovascular events: Results of the CLEAR Outcomes study and subgroup analyses","volume":"26","author":"Colivicchi","year":"2025","journal-title":"G. Ital. Cardiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1003","DOI":"10.1002\/hsr2.1003","article-title":"Retrospective multicenter registry for endovascular treatment with newer devices in over 25-cm femoropopliteal artery disease: A retrospective observational study","volume":"6","author":"Horie","year":"2023","journal-title":"Health Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/15266028241241248","article-title":"A Systematic Review and Meta-Analysis of Efficacy and Safety of Cilostazol Prescription in Patients With Femoropopliteal Peripheral Artery Disease After Endovascular Therapy","volume":"32","author":"Tan","year":"2025","journal-title":"J. Endovasc. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1024\/0301-1526\/a001114","article-title":"Cilostazol for peripheral arterial disease\u2014A position paper from the Italian Society for Angiology and Vascular Medicine","volume":"53","author":"Martini","year":"2024","journal-title":"Vasa"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Shi, M., Jian, L., Liu, X., Liu, F., Liu, Y., Yang, X., Liu, X., Xiong, H., Wang, D., and Song, P. (2025). Development and Validation of Overall Survival and Amputation-Free Survival Prediction Models for Patients with Peripheral Arterial Disease Who underwent Endovascular Therapy. J. Endovasc. Ther., 15266028251328474.","DOI":"10.1177\/15266028251328474"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.avsg.2023.12.071","article-title":"The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions","volume":"103","author":"Alameddine","year":"2024","journal-title":"Ann. Vasc. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jvs.2024.08.032","article-title":"Cilostazol after endovascular therapy for femoropopliteal peripheral arterial disease: A systematic review and meta-analysis","volume":"81","author":"Cerecedo","year":"2025","journal-title":"J. Vasc. Surg."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e018184","DOI":"10.1161\/JAHA.120.018184","article-title":"Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events","volume":"10","author":"Kalantzi","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_115","first-page":"e80929","article-title":"Effects of Cilostazol and Aspirin on Diabetic Foot Ulcer and Peripheral Artery Disease: A Retrospective Study","volume":"17","author":"Jayalal","year":"2025","journal-title":"Cureus"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"120634","DOI":"10.1016\/j.atherosclerosis.2025.120634","article-title":"Effects of cilostazol on the prognosis of lower extremity peripheral arterial disease in patients with diabetes mellitus in Korea: A nationwide population-based study","volume":"413","author":"Moon","year":"2026","journal-title":"Atherosclerosis"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jjcc.2021.11.011","article-title":"Comprehensive cardiac rehabilitation program for peripheral arterial diseases","volume":"80","author":"Yasu","year":"2022","journal-title":"J. Cardiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e034175","DOI":"10.1161\/JAHA.123.034175","article-title":"Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study","volume":"14","author":"Chou","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2337\/dc24-1546","article-title":"Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes","volume":"48","author":"Griffin","year":"2025","journal-title":"Diabetes Care"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ejvs.2021.09.031","article-title":"Initiation of SGLT2 Inhibitors and the Risk of Lower Extremity Minor and Major Amputation in Patients with Type 2 Diabetes and Peripheral Arterial Disease: A Health Claims Data Analysis","volume":"62","author":"Rodionov","year":"2021","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cjco.2022.01.003","article-title":"Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events","volume":"4","author":"Boczar","year":"2022","journal-title":"CJC Open"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"oeae063","DOI":"10.1093\/ehjopen\/oeae063","article-title":"Colchicine improves clinical outcomes in patients with coronary disease, will it result in similar benefits in peripheral artery disease?","volume":"4","author":"Tardif","year":"2024","journal-title":"Eur. Heart J. Open"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijpvm.IJPVM_125_20","article-title":"The Cost-Effectiveness and Cost-Utility of Statin Drug for the Treatment of Patients with Cardiovascular Disease, A Systematic Review","volume":"12","author":"Eisavi","year":"2021","journal-title":"Int. J. Prev. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience","volume":"105","author":"Gurgoze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Mercep, I., Strikic, D., Hrabac, P., Pecin, I., and Reiner, Z. (2024). PCSK9 inhibition: From effectiveness to cost-effectiveness. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1339487"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Sasidharan, A., Bagepally, B.S., Kumar, S.S., Jagadeesh, K.V., and Natarajan, M. (2022). Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. PLoS ONE, 17.","DOI":"10.1101\/2022.02.14.22270957"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40256-025-00753-w","article-title":"Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial","volume":"26","author":"Nicholls","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Toth, P.P., Ferrieres, J., Waters, M., Mortensen, M.B., Lan, N.S.R., and Wong, N.D. (2023). Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1220017"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e024992","DOI":"10.1161\/JAHA.121.024992","article-title":"Cost-Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke","volume":"11","author":"Zhou","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Goudarzi, Z., Najafpour, Z., Gholami, A., Keshavarz, K., Mojahedian, M.M., and Babayi, M.M. (2025). Cost-effectiveness and budget impact analysis of rivaroxaban with or without aspirin compared to aspirin alone in patients with coronary and peripheral artery diseases in Iran. BMC Health Serv. Res., 25.","DOI":"10.1186\/s12913-025-12431-3"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamacardio.2023.0077","article-title":"Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction","volume":"8","author":"Cohen","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse Effects of GLP-1 Receptor Agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"97","DOI":"10.17476\/jmbs.2025.14.2.97","article-title":"Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic\/Bariatric Surgery","volume":"14","author":"Huh","year":"2025","journal-title":"J. Metab. Bariatr. Surg."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.clinthera.2017.07.036","article-title":"Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis","volume":"39","author":"Wu","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lin, W.Q., Cai, Z.J., Chen, T., Liu, M.B., Li, N., and Zheng, B. (2021). Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.684960"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Khan, H., Girdharry, N.R., Massin, S.Z., Abu-Raisi, M., Saposnik, G., Mamdani, M., and Qadura, M. (2025). Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature. Metabolites, 15.","DOI":"10.3390\/metabo15040224"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1024\/0301-1526\/a001117","article-title":"A systematic review of the neutrophil to lymphocyte and platelet to lymphocyte ratios in patients with lower extremity arterial disease","volume":"53","author":"Bradley","year":"2024","journal-title":"Vasa"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:28:28Z","timestamp":1780547308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/6\/789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":152,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["biom16060789"],"URL":"https:\/\/doi.org\/10.3390\/biom16060789","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}